Discover
IGC
IGC Pharma, Inc.
0.27
200 x undefined
400 x undefined
bid
ask
+
0.00
0.99%
300 @ 05:24 AM
0.27 +0.00 (0.00%)
| Ytd | -1.89% | |
| 1y | -8.43% |
0.27
day range
0.28
0.24
52 week range
0.50
| Open | 0.27 | Prev Close | 0.27 | Low | 0.27 | High | 0.28 | Mkt Cap | 27.50M |
| Vol | 219.00K | Avg Vol | 1.26M | EPS | -0.06 | P/E | N/A | Forward P/E | -3.74 |
| Beta | 1.29 | Short Ratio | 2.29 | Inst. Own | 22.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 0.30 | 200-d Avg | 0.32 | 1yr Est | 3.75 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-02-12 | 2024-12 | -0.03 | N/A | N/A | N/A |
| 2024-11-12 | 2024-09 | -0.03 | -0.02 | 0.01 | 33.33% |
| 2024-08-08 | 2024-06 | 0 | -0.03 | N/A | N/A |
| 2024-06-24 | 2024-03 | 0 | -0.04 | N/A | N/A |
| 2024-02-14 | 2023-12 | 0 | -0.09 | N/A | N/A |
| 2023-11-09 | 2023-09 | 0 | -0.05 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-05 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-09-03 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-07-29 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-07-17 | Alliance Global Partners | Upgrade | Buy | |
| 2024-06-21 | Ascendiant Capital | Upgrade | Buy | Buy |
Profile
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-03-21 | BRADBURY STRATEGIC INVESTMENT FUND A | Beneficial Owner of more than 10% of a Class of Security | 13.82M | Stock Award(Grant) |
| 2024-03-12 | GRIMALDI CLAUDIA | Director | 1.04M | Conversion of Exercise of derivative security |
| 2024-09-24 | MORAN JAMES P | Director | 0.00 | Purchase |
| 2024-03-12 | MUKUNDA RAM | Chief Executive Officer | 4.34M | Stock Gift |
| 2024-08-11 | PRINS RICHARD K | Director | 1.04M | Stock Gift |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 703.80K | 263.01K | 1.78% |
| 2024-09-29 | Vanguard Group Inc | 645.17K | 241.10K | 1.63% |
| 2024-09-29 | Geode Capital Management, LLC | 562.97K | 210.38K | 1.42% |
| 2024-09-29 | State Street Corporation | 165.31K | 61.78K | 0.42% |
| 2024-09-29 | Virtu Financial LLC | 123.06K | 45.99K | 0.31% |
| 2024-09-29 | Dearborn Partners, L.L.C. | 116.40K | 43.50K | 0.29% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Extended Market Index Fund | 630.22K | 235.51K | 1.59% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 387.26K | 144.72K | 0.98% |
| 2024-10-30 | Fidelity Total Market Index Fund | 99.14K | 37.05K | 0.25% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 91.47K | 34.18K | 0.23% |
Split
| Split | Date |
|---|---|
| 0.1 : 1 | 2013-04-19 |